Akari Therapeutics PLC (AKTX) intrinsic value & 10-year financials
Akari Therapeutics PLC (AKTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $8.18
- Market cap
- $550.7B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -418.8%
- Free cash flow (FY2025)
- —
AKTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$17.3M | $0.00 | — | — | -64.6% |
| FY2024 | — | -$19.8M | $0.00 | — | — | -196.8% |
| FY2023 | — | -$10.0M | $0.00 | — | — | -2151.9% |
| FY2022 | — | -$17.7M | $0.00 | — | — | -483.2% |
| FY2021 | — | — | — | — | — | — |
| FY2015 | — | -$45.3M | — | -$5.0M | — | -114.2% |
| FY2014 | — | -$9.6M | — | -$9.5M | — | -190.8% |
| FY2013 | — | -$3.6M | — | -$5.5M | — | -295.0% |
| FY2012 | — | -$4.3M | — | -$2.1M | — | 146.0% |
| FY2011 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Akari Therapeutics Plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Akari Therapeutics Plc has historically struggled to out-earn its cost of capital, averaging just -8.2% ROIC.
Akari Therapeutics Plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Akari Therapeutics Plc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.